Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04332367 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 10, 2026 (before its estimated September 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary and study completion pushed from Apr 2026 to Sep 30, 2026v10
  2. Re-verified, no change to tracked fieldsv9
  3. Primary and study completion dates: Apr 2025 to Apr 2026v8
  4. 2 versions Re-verified since Oct 16, 2024, no change to tracked fieldsv6-v7
  5. Primary and study completion dates: May 2024 to Apr 2025 Start date: Dec 19, 2019 to Aug 1, 2020v5 Show 1 more changeShow less
    • Start date: Dec 19, 2019 to Aug 1, 2020
Show 3 earlier versionsHide 3 earlier versions
  1. Primary completion date: Dec 2022 to May 2024 Completion date: Dec 2024 to May 2024v4 Show 1 more changeShow less
    • Completion date: Dec 2024 to May 2024
  2. 2 versions Re-verified since Jan 11, 2021, no change to tracked fieldsv2-v3
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung cancer. This study will also assess whether it is safe to combine these drugs.
Trial Details
NCT Number NCT04332367
Lead Sponsor Abramson Cancer Center at Penn Medicine
Conditions Non-small Cell Lung Cancer
Enrollment 59 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov